Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site

References

• JensenJDKnoopAEwertzMLaenkholmAVER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancerBreast Cancer Res Treat2012132251152121667123
   PubMed Web of Science ®Google Scholar
• BroomRJTangPASimmonsCChanges in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancerAnticancer Res20092951557156219443366
   PubMed Web of Science ®Google Scholar
• LowerEEGlassEBlauRHarmanSHER-2/neu expression in primary and metastatic breast cancerBreast Cancer Res Treat2009113230130618273700
   PubMed Web of Science ®Google Scholar
• LowerEEGlassELBradleyDABlauRHeffelfingerSImpact of metastatic estrogen receptor and progesterone receptor status on survivalBreast Cancer Res Treat2005901657015770528
   PubMed Web of Science ®Google Scholar
• LowerEEKhanSBiomarker discordance: why it occurs and why it is importantCancer Biomark2012–2013126219230
   Web of Science ®Google Scholar
• Van PoznakCSomerfieldMRBastRCUse of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical Practice GuidelineJ Clin Oncol201533242695270426195705
   PubMed Web of Science ®Google Scholar
• RoccaAFarolfiAMaltoniREfficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancerBreast Cancer Res Treat20151521576526012644
   PubMed Web of Science ®Google Scholar
• KulkaJSzékelyBLukácsLVComparison of predictive immunohistochemical marker expression of primary breast cancer and paired distant metastasis using surgical material: a practice-based studyJ Histochem Cytochem201664425626727029768
   PubMed Web of Science ®Google Scholar
• LiMHHouCLWangCSunAJHER-2, ER, PR status concordance in primary breast cancer and corresponding metastatic lesion in lymph node in Chinese womenPathol Res Pract2016212425225726899763
   PubMed Web of Science ®Google Scholar
• DomanskiAMMonsefNDomanskiHAGrabauDFernöMComparison of the oestrogen and progesterone receptor status in primary breast carcinomas as evaluated by immunohistochemistry and immunocytochemistry: a consecutive series of 267 patientsCytopathology2013241212522783929
   PubMed Web of Science ®Google Scholar
• WolffACHammondMEHicksDGRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol201331313997401324101045
   PubMed Web of Science ®Google Scholar
• HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol201028162784279520404251
   PubMed Web of Science ®Google Scholar
• SinghKTantravahiULommeMMPasquarielloTSteinhoffMSungCJUpdated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancersBreast Cancer Res Treat2016157340541127180259
   PubMed Web of Science ®Google Scholar
• KarlssonEAppelgrenJSolterbeckABergenheimMAlvarizaVBerghJBreast cancer during follow-up and progression – A population based cohort on new cancers and changed biologyEur J Cancer201450172916292425241230
   PubMed Web of Science ®Google Scholar
• IbrahimTFarolfiAScarpiEHormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impactOncology201384315015723257904
   PubMed Web of Science ®Google Scholar
• BaJLLiuCGJinFAlterations in hormonal receptor expression and HER2 status between primary breast tumors and paired nodal metastases: discordance rates and prognosisAsian Pac J Cancer Prev201415219233923925422206
   PubMedGoogle Scholar
• MatsumotoAJinnoHMurataTPrognostic implications of receptor discordance between primary and recurrent breast cancerInt J Clin Oncol201520470170825348193
   PubMed Web of Science ®Google Scholar
• Karagöz ÖzenDSOzturkMAAydinÖTurnaZHIlvanSÖzguroglüMReceptor expression discrepancy between primary and metastatic breast cancer lesionsOncol Res Treat2014371162262625427579
   PubMed Web of Science ®Google Scholar
• NiikuraNLiuJHayashiNLoss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-over-expressing primary breast tumorsJ Clin Oncol201230659359922124109
   PubMed Web of Science ®Google Scholar
• YangYFLiaoYYYangMPengNFXieSRXieYFDiscordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patientsMed Oncol2014311021425216864
   PubMed Web of Science ®Google Scholar
• TurnerNHDi LeoAHER2 discordance between primary and metastatic breast cancer: assessing the clinical impactCancer Treat Rev201339894795723764178
   PubMed Web of Science ®Google Scholar
• AsoganABHongGSArni PrabhakaranSKConcordance between core needle biopsy and surgical specimen for ER, PgR and Her2neu receptor status in breast cancer and study of difference in reliability between the two groups with the change in ASCO/CAP guidelinesSingapore Med J201610
   Google Scholar
• VianiGAAfonsoSLStefanoEJDe FendiLISoaresFVAdjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trialsBMC Cancer2007715317686164
   PubMed Web of Science ®Google Scholar